NL
NBIX icon

Navalign LLC’s Neurocrine Biosciences NBIX Stock Holding History

Navalign LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Sell
1,818
-1,251
-41% -$186K 0.07% 108
2026
Q1 		$404K Sell
3,069
-540
-15% -$71.6K 0.1% 97
2025
Q4 		$512K Hold
3,609
– – 0.13% 91
2025
Q3 		$507K Buy
+3,609
New +$489K 0.13% 90

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Navalign LLC's NBIX Position: Q2 2026 in Review

Navalign LLC reduced its Neurocrine Biosciences (NBIX) stake by 41% in Q2 2026, selling an estimated $186K and leaving 1,818 shares worth $306K. The position accounts for 0.07% of the portfolio, ranked #108.

Navalign LLC first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $512K in Q4 2025. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Navalign LLC held 1,818 shares of Neurocrine Biosciences worth $306K as of Q2 2026.
  • Navalign LLC sold 1,251 Neurocrine Biosciences shares in Q2 2026, an estimated $186K.
  • Neurocrine Biosciences made up 0.07% of Navalign LLC's portfolio in Q2 2026, its #108 holding.
  • Navalign LLC first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Navalign LLC's Neurocrine Biosciences position peaked at $512K in Q4 2025.
  • 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Navalign LLC's 13F filing for Q2 2026, filed 28 Jul 2026.